Circulating microRNA in Heart Failure-Practical Guidebook to Clinical Application

Cardiol Rev. 2022 Jan-Feb;30(1):16-23. doi: 10.1097/CRD.0000000000000352.

Abstract

Heart failure (HF) remains a major cause of death and disability worldwide. Currently, B-type natriuretic peptide and N-terminal probrain natriuretic peptide are diagnostic biomarkers used in HF. Although very sensitive, they are not specific enough and do not allow the prediction or early diagnosis of HF. Many ongoing studies focus on determining the underlying cause and understanding the mechanisms of HF on the cellular level. MicroRNAs (miRNAs) are noncoding RNAs, which control the majority of cellular processes and therefore are considered to have a potential clinical application in HF. In this review, we aim to provide synthesized information about miRNAs associated with ejection fraction, HF etiology, diagnosis, and prognosis, as well as outline therapeutic application of miRNAs in HF. Further, we discuss methodological challenges associated with the analysis of miRNAs and provide recommendations for defining a study population, collecting blood samples, and selecting detection methods to study miRNAs in a reliable and reproducible way. This review is intended to be an accessible tool for clinicians interested in the field of miRNAs and HF.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Circulating MicroRNA* / blood
  • Heart Failure* / diagnosis
  • Heart Failure* / therapy
  • Humans
  • MicroRNAs / therapeutic use
  • Practice Guidelines as Topic

Substances

  • Biomarkers
  • Circulating MicroRNA
  • MicroRNAs